Treatment of Refractory Pruritus with Dupilumab in a Patient with Dermatomyositis

Main Article Content

Nate Bowers
William Huang


Dermatomyositis, Dupilumab


Abstract not available.


1. Giris M, Durmus H, Yetimler B, Tasli H, Parman Y, Tuzun E. Elevated IL-4 and IFN-gamma Levels in Muscle Tissue of Patients with Dermatomyositis. In Vivo. Jul-Aug 2017;31(4):657-660. doi:10.21873/invivo.11108

2. Ishii W, Matsuda M, Shimojima Y, Itoh S, Sumida T, Ikeda S. Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med. 2008;47(18):1593-9. doi:10.2169/internalmedicine.47.0967

3. Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. Jan 2019;143(1):155-172. doi:10.1016/j.jaci.2018.08.022

4. Kim HJ, Zeidi M, Bonciani D, et al. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol. Sep 2018;179(3):669-678. doi:10.1111/bjd.16498

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)